Dosing for Neomycin-Polymyxin-Dexamethasone Ophthalmic Suspension
Instill 1 to 2 drops into the conjunctival sac(s), with frequency ranging from hourly in severe disease (tapered as inflammation subsides) to 4-6 times daily in mild disease. 1
Dosing Algorithm Based on Disease Severity
Severe Disease
- Initial dosing: 1-2 drops hourly into the affected eye(s) 1
- Taper: Gradually reduce frequency as inflammation subsides 1
- This aggressive approach is reserved for significant inflammatory conditions requiring intensive steroid coverage
Mild Disease
- Dosing: 1-2 drops up to 4-6 times daily 1
- This represents the standard regimen for routine post-operative inflammation or mild inflammatory conditions
Critical Prescribing Limitations
Do not prescribe more than 20 mL initially, and do not refill without re-evaluation. 1 This restriction exists because:
- Prolonged steroid use increases risk of elevated intraocular pressure
- Extended antibiotic exposure can lead to sensitization reactions
- The combination requires monitoring for complications
Route of Administration
Formulation Details
Each mL contains neomycin sulfate equivalent to 3.5 mg neomycin, polymyxin B sulfate 10,000 units, and dexamethasone 0.1%. 1
Common Pitfalls and Caveats
Allergic reactions to neomycin are relatively common. In comparative studies, patients receiving neomycin-containing combinations experienced significantly more treatment-related ocular allergic reactions compared to alternative antibiotics, with withdrawal rates up to 9% due to allergic reactions. 2 Monitor for signs of hypersensitivity including increased redness, itching, or worsening symptoms.
Long-term use (beyond 4 months) has been associated with punctal stenosis, particularly when used as ongoing anti-inflammatory therapy. 3 This complication manifests as epiphora and fibrotic tissue over the nasolacrimal puncta.
Systemic absorption does occur with topical ophthalmic steroids, potentially suppressing endogenous cortisol production with prolonged use. 4 While this data comes from veterinary studies, it highlights the importance of limiting treatment duration in humans as well.